跳至主要内容

Fosun Health Capital reached a cooperation agreement with Medicilon to explore innovative drug research and development together

 On July 25, 2023, Fosun Health Capital established by Fosun Pharma（stock code:600196.SH), reached a strategic partnership with Medicilon（stock code: 688202.SH). Meanwhile StarMab Biology (Suzhou) ( referred to as "StarMab Biology"，jointly invested by the innovation drug research fund of Fosun Group and Yaopharma) and Medicilon entered into a strategic cooperation for innovative drug IND research and application services. This strategic partnership indicates a significant step forward in the cooperation between Fosun Health Capital and Medicilon, with milestone for both parties' development.

Cui Zhiping, Co-CEO and General Manager of Fosun Health Capital, Chen Chunlin, Founder and CEO of Medicilon, along with members from both sides attended the signing ceremony together and witnessed the contract.

The signing ceremony.webp

According to the strategic cooperation agreement, Medicilon will leverage its international perspective and rich experience in R&D to provide innovative drug enterprises invested by Fosun Health Capital with services，such as drug discovery, pharmaceutical research, preclinical research, IND registration declaration, etc., aiming to facilitate cooperation in 10 innovative drug IND projects. Medicilon will also provide professional opinions on the rationality of product development clinical programs, product success probability analysis, product market potential, etc. Furthermore, Medicilon will facilitate investment cooperation and create an ecosystem linking innovative drug investment and business cooperation. As for StarMab Biology, Medicilon will provide comprehensive and high-quality preclinical research services. Through this strategic cooperation, all parties will integrate respective technology, market and talent advantages, embrace the trends and technological changes in bioengineering and pharmaceutical industry, promote deeper and broader exploration in various fields, and explore the possibilities of new drug development.

About Fosun Health Capital:
As the first VC fund in the field of new drugs initiated by Fosun Pharma, Fosun Health Capital primarily invests biopharmaceutical sector projects in early-stage and expansion-stage, which have technological innovation and rapid growth potential. It is committed to incubating high-quality projects from universities and research institutes and introducing leading overseas biotechnology technologies and products to China through introduction and cooperation models.

About Medicilon:
Medicilon as an integrated CRO provides comprehensive one-stop R&D services for pharmaceutical enterprises and scientific research institutions around the world. Medicilon has built an integrated platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, to provide  comprehensive preclinical R&D services for the global biomedical industry.

标签：

评论

发表评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou
发表评论
阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d
发表评论
阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati
发表评论
阅读全文